click below
click below
Normal Size Small Size show me how
APC2 Quiz 4
Endocrine 1
| Brand | Generic | Category | Indications | Essential Knowledge |
|---|---|---|---|---|
| Fortamet, Glumetza | metformin (PO) | Biguanide | Type 2 DM, PCOS | Key Side Effects: diarrhea, nausea, vomiting, Vitamin B12 deficiency Other Notes: CI with eGFR <30; US Boxed Warnings: lactic acidosis |
| Januvia, Zituvio | sitagliptin (PO) | Dipeptidyl peptidase (DPP-4) inhibitor | Type 2 DM | Key Side Effects: nasopharyngitis |
| Jardiance | empagliflozin (PO) | Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | Type 2 DM, HF, CKD | Key Side Effects: genital mycotic infections, UTI |
| Farxiga | dapagliflozin (PO) | Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | Type 2 DM, HF, CKD | Key Side Effects: genital mycotic infections, UTI |
| Amaryl | glimepiride (PO) | Sulfonylurea | Type 2 DM | Key Side Effects: hypoglycemia, weight gain |
| Glucotrol, Glucotrol XL | glipizide (PO) | Sulfonylurea | Type 2 DM | Key Side Effects: hypoglycemia, weight gain |
| Actos | pioglitazone (PO) | Thiazolidinedione (TZD) | Type 2 DM | Key Side Effects: peripheral edema, weight gain, upper respiratory tract infection; increased risk of fractures and bladder cancer US Boxed Warnings: may exacerbate congestive heart failure and CI in NYHA Class III and IV |
| Trulicity | dulaglutide (SQ) | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM | Key Side Effects: nausea, vomiting, diarrhea, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 |
| Victoza, Saxenda | liraglutide (SQ) | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 |
| SQ: Ozempic, Wegovy PO: Rybelsus | semaglutide (PO, SQ) | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 |
| Mounjaro, Zepbound | tirzepatide (SQ) | Dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist | Type 2 DM, chronic weight management | Key Side Effects: nausea, vomiting, diarrhea, constipation, increased heart rate, pancreatitis US Boxed Warning: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer and in patients with multiple endocrine neoplasia syndrome type 2 |
| Lantus, Toujeo, Basaglar | insulin glargine (SQ) | Insulin, long acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain |
| Humulin N, Novolin N | insulin NPH (SQ) (OTC) | Insulin, intermediate acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain |
| Novolog | insulin aspart (SQ) | Insulin, rapid acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain |
| Humalog | insulin lispro (SQ) | Insulin, rapid acting | Type 1 DM, type 2 DM | Key Side Effects: hypoglycemia, weight gain |
| Humulin R, Novolin R | insulin regular (SQ, IV) SQ: OTC | Insulin, short-acting | Type 1 DM, type 2 DM, DKA | Key Side Effects: hypoglycemia, weight gain |